« Back to Record
Citation APA

Collet, L., Noël, J.-C., Catteau, X., Ardin, M., Berthet, J., Ghamry-Barrin, S., Treilleux, I., Bengrine Lefevre, L., Martinez, M., Rothé, F., Sotiriou, C., Caux, C., Dubois, B., Ray-Coquard, I., & Le Saux, O. (2025). Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial. ESMO Open, 10(6), 105104. doi:10.1016/j.esmoop.2025.105104


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/392401

Collet, L., Noël, J.-C., Catteau, X., Ardin, M., Berthet, J., Ghamry-Barrin, S., Treilleux, I., Bengrine Lefevre, L., Martinez, M., Rothé, F., Sotiriou, C., Caux, C., Dubois, B., Ray-Coquard, I., & Le Saux, O. (2025). Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial. ESMO Open, 10(6), 105104. doi:10.1016/j.esmoop.2025.105104